Jonathan W. Ayers - 11 May 2022 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 May 2022, 17:36:54 UTC
Prior SEC filing
22 Feb 2022
Next SEC filing
08 Sep 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers

Key filing fact

Jonathan W. Ayers filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 13 May 2022.

Key facts

  • This page summarizes Jonathan W. Ayers's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
  • 4 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 13 May 2022, 17:36.

Change

  • Previous filing in this sequence was filed on 22 Feb 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+224
Change %
+0.04%
Price
$0.000000
Shares after
630,420
Date
11 May 2022
Ownership
Direct
IDXX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,000
Date
11 May 2022
Ownership
by Ayers Family Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Award

Transaction value
Shares
+945
Change %
Price
Shares after
945
Date
11 May 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
945
Exercise price
$333.90
Footnotes
F1, F4
IDXX transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares
+344
Change %
+154%
Price
Shares after
568
Date
11 May 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
344
Exercise price
Footnotes
F2, F4
IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares
-224
Change %
-39%
Price
Shares after
344
Date
11 May 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
224
Exercise price
Footnotes
F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.

Footnote F4

Not applicable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .